Lupin has forayed into over-the-counter (OTC) segment in the country and plans to achieve Rs.300 crore turnover in the vertical in the next 5 years.

Lupin has introduced ‘Softovac’, its legacy product as an OTC medicine across the country. Anil Kaushal, Lupin Head-OTC Business stated, “It was imperative for us to enter the OTC segment as the vertical has been steadily growing over the years in the country. Over a horizon of five years we are looking at a turnover of Rs.300 crore from the business.”

Furthermore, Nilesh Gupta, Managing Director Lupin stated, “The OTC segment is one of the fastest growing segments in the Indian pharmaceutical market. This, combined with our capabilities and expertise in this space, makes it a lucrative business opportunity for Lupin.”

Read EquityPandit’s Technical Analysis of Lupin Outlook for the Week